Latest news with #nasalspray
Yahoo
16 hours ago
- Business
- Yahoo
Aptar's First Nasal Pump Made with 52% Bio-based Material* now Available with Haleon's Otrivin® Brand
The Freepod® nasal spray pump, globally used with the Otrivin® brand, is now made from 52% bio-based feedstock CRYSTAL LAKE, Ill., July 29, 2025--(BUSINESS WIRE)--Aptar Pharma, a global leader in drug delivery and active material science solutions and services, is proud to announce that its Freepod® nasal spray pump - one of the delivery systems for Haleon's Otrivin® brand - is now made with mass balance bio-based resins. This is the first Aptar delivery system using such materials to be commercialized globally. The use of more sustainable renewable plastic resources is a meaningful measure to help reduce the use of fossil-based materials in healthcare primary packaging. Reinforcing circularity in pharmaceutical packaging Aptar Pharma's Freepod® spray pump used with Haleon's Otrivin® Nasal Spray is made of 52% ISCC Plus certified bio-based feedstock. The bottle is produced using a mass balance approach equivalent to 100% bio-based content. Together, the pump and bottle components result in an overall circular material content of 60% for the full nasal spray device. ISCC PLUS certified manufacturing and supply chain Aptar Pharma is committed to helping its customers meet their sustainability goals, such as reducing the use of fossil-based materials in packaging. The Freepod® nasal spray components are made from bio-based resins derived from renewable feedstocks like bio-waste and residual oils, using an ISCC PLUS-certified mass balance approach. The Aptar Pharma manufacturing site in Mezzovico, Switzerland, is ISCC PLUS certified, ensuring full traceability of materials throughout the manufacturing process and supply chain. ISCC Plus certification also covers all external suppliers - including injection molding providers, service partners, and warehouses - guaranteeing a fully (ISCC) certified supply chain for the Freepod® components. Partnership for a more sustainable approach The joint sustainability approach between Haleon (formerly GSK Consumer Healthcare) and Aptar Pharma is built on a long-term partnership spanning over 30 years. This collaboration has led to significant achievements, including the Otrivin® Freepod® winning the World Packaging Award in 2019 for its innovative and sustainable design. The use of bio-based or renewable feedstocks for the Otrivin® products with Freepod® technology supports Haleon's goal to reduce virgin petroleum-based plastic use by 10% by 2025** and by a third by 2030, compared to 2022 levels. Aptar Pharma's Freepod® for Otrivin®, available globally, demonstrates Aptar's commitment to sustainability and innovation. Looking ahead, this collaboration is anticipated to extend to Otrivin Nasal Mist, Haleon's latest microdroplet technology, which is being rolled out globally since 2023. "At Aptar, sustainability is not just a responsibility - it's a strategic advantage," commented Gael Touya, President of Aptar Pharma. "The launch of Freepod® Futurity™ reflects our commitment to developing solutions that respond to consumers' increasing demand for more sustainable healthcare delivery technologies. As a trusted partner to Haleon, we are proud to help drive the success of the Otrivin® brand while enabling a shift away from fossil-based materials in primary packaging. Supporting our partners in reaching their environmental goals reinforces our vision of supporting the healthcare industry, from Formulation to patient." With a strong commitment to sustainability, Aptar Pharma continuously strives to reduce its environmental impact and support its partners in achieving their sustainability goals. *ISCC Plus certified bio-based feedstock, mass balance approach.**The end point for the goal delivery period is the end of the 2025 calendar year. About Aptar Pharma Aptar Pharma is part of AptarGroup, Inc. (NYSE:ATR), a global leader in the design and manufacturing of a broad range of drug delivery, consumer product dispensing and active material science solutions. Aptar's innovative solutions and services serve a variety of end markets including pharmaceutical, beauty, personal care, home, food and beverage. Using insights, proprietary design, engineering and science to create dispensing, dosing and protective technologies for many of the world's leading brands, Aptar in turn makes a meaningful difference in the lives, looks, health and homes of millions of patients and consumers around the world. Aptar is headquartered in Crystal Lake, Illinois and has over 13,000 dedicated employees in 20 countries. For more information, visit About Haleon Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose to deliver better everyday health with humanity. Haleon's product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on trusted science, innovation and deep human understanding. View source version on Contacts Media Contact: Ciara JacksonAptar Pharma+49 151 1951
Daily Mail
18-07-2025
- Health
- Daily Mail
First needle-free treatment for life-threatening allergic reactions will be made available in the UK as a nasal spray
The first needle-free treatment for life-threatening allergic reactions will be made available in the UK as a nasal spray. The medicines regulator has approved the drug EURneffy for emergency use in a move welcomed by allergy campaigners. They say it provides an 'easier and more accessible' alternative to injectable epipens, which are currently used to treat severe reactions, known as anaphylaxis. Companies are required by law to clearly tell customers if their food contains any of 14 specified allergens, which have the potential to kill. These include nuts, crustaceans, eggs, fish, milk, mustard and sesame. Some people also suffer fatal reactions to insect stings and medicines. Tanya Ednan-Laperouse, whose daughter Natasha died in 2016 after eating a Pret baguette containing sesame, said: 'The number of people experiencing anaphylaxis triggered by food has increased dramatically over the last 20 years. 'But we know that some people are reluctant to use the current adrenaline auto-injectors in the event of anaphylaxis due to a fear of needles and hurting someone. 'This can delay administering adrenaline, and in a food allergy emergency every second counts. 'The nasal spray will be an easier and more accessible way of administering this life-saving medication, and is great news for people living with food allergies.' Mrs Ednan-Laperouse, who founded food allergy charity the Natasha Allergy Research Foundation in her daughter's name, added: 'Spare supplies of these nasal adrenaline devices should now be another option available to schools.' The Food Standards Agency says up to 2 per cent of adults and 8 per cent of children in the UK live with a food allergy. Anaphylaxis is a sudden and life-threatening allergic reaction that can cause a drop in blood pressure and breathing difficulties. More than 7,000 birth certificates a year in the mention anaphylactic shock, according to the Office for National Statistics. EURneffy, which contains adrenaline, is intended for use in adults and children who weigh 30kg (66lb) or more, and can be used even if people have colds or blocked noses. It is a single dose nasal spray that delivers its entire contents (2mg) upon activation. People are reminded the plunger should not be pressed before inserting the product into the nostril, otherwise the single dose will be lost. Julian Beach, from the Medicines and Healthcare products Regulatory Agency, said: 'Patient safety is our top priority, which is why we're pleased to approve the first needle-free nasal spray formulation of adrenaline for the emergency treatment of anaphylaxis in the UK. 'Until now, adrenaline for self-administration has only been available via auto-injectors. 'While this represents an important new option, adrenaline auto-injectors remain a vital and potentially life-saving treatment, giving people experiencing anaphylaxis valuable time before emergency help arrives. 'We continue to encourage everyone at risk of severe allergic reactions, and those around them, to familiarise themselves with how to respond in an emergency. 'Resources and guidance are available on the MHRA website to help people be prepared.' The MHRA said patients should always carry two nasal sprays with them in case a second dose is needed, and tell family and friends where it is. A spokeswoman for the drug firm behind the spray, ALK, said: 'The market launch in the UK is expected within the coming months once market access negotiations are completed.' ALK is having ongoing discussions to agree a price with the Department of Health and Social Care. Once an NHS list price has been agreed and the product is available, doctors will be able to prescribe the nasal spray.
Medscape
18-07-2025
- Health
- Medscape
MHRA Approves UK's First Nasal Spray for Anaphylaxis
An adrenaline nasal spray for the emergency treatment of anaphylaxis has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA). This marks the first time a needle-free formulation is available in the UK for this use. The spray, called EURneffy, is manufactured by ALK-Abelló A/S, a pharmaceutical company based in Denmark. It was authorised for use in the European Union in August 2023. UK approval followed the MHRA's International Recognition Procedure, introduced in January 2024. The pathway enables the MHRA to align with decisions made by trusted global regulatory partners. Alternative to Adrenaline Auto-Injectors Adrenaline is the standard emergency treatment for anaphylaxis and is usually administered by auto-injectors pens. EURneffy is the first approved nasal spray alternative. The ready-to-use spray is suitable for adults and children weighing 30 kg (about 66 lbs) or more. It delivers its entire contents of 2 mg of adrenaline with a single activation, even when the user has nasal congestion. It is indicated for the emergency treatment of allergic reactions caused by insect stings or bites, foods, medicinal products, and other allergens. It can also be used to treat idiopathic or exercise-induced anaphylaxis. According to ALK-Abelló, the product offers a 30-month shelf life and better temperature stability compared with traditional adrenaline auto-injectors. Patients Should Always Carry Two Doses Patients are advised to carry two doses of adrenaline in case a second dose is needed. A second dose should be given in the same nostril after 10 minutes if symptoms persist or recur. Patients should also inform friends or family about their condition in case help is needed during a reaction. Biphasic anaphylaxis — a delayed recurrence of symptoms — remains a risk. Patients should seek immediate medical attention after any severe allergic reaction, regardless of whether symptoms resolve. The MHRA cautioned that the spray's plunger must not be pressed before insertion into the nostril, as this will release the single dose prematurely. Efficacy and Tolerability Supported by Trial Data Presentations at the European Academy of Allergy and Clinical Immunology congress last month in Glasgow highlighted that Eurneffy nasal adrenaline spray addressed "unmet needs and current challenges in the emergency management of anaphylaxis". Ethical and practical constraints prevent trials in patients experiencing acute anaphylaxis. However, data from ALK-Abelló's development programme, involving more than 700 participants, demonstrated that the spray produced a pharmacological response comparable with that of intramuscular adrenaline auto-injectors. Real-world data also supported the effectiveness of the nasal adrenaline spray in acute situations. No serious adverse events were reported in clinical studies. The most frequently occurring adverse reactions were reported only after a second 2 mg dose (4 mg total). These included throat irritation (18.8%), headache (17.6%), nasal discomfort (12.9%), and feeling jittery (10.6%). Ongoing Safety Monitoring The MHRA will continue to monitor the safety and effectiveness of Eurneffy. Healthcare professionals and patients are urged to report suspected side effects through the Yellow Card scheme. Further information, including the Patient Information Leaflet and Summary of Product Characteristics, will be available on the MHRA website within seven days of approval.
Telegraph
18-07-2025
- Health
- Telegraph
First nasal spray for allergic reactions now available in UK
The first needle-free emergency treatment for anaphylaxis – in the form of a nasal spray – will now be available in the UK. The Medicines and Healthcare products Regulatory Agency (MHRA) has approved the adrenaline (epinephrine) nasal spray (EURneffy) for emergency treatment. The manufacturer, ARS Pharma, has been contacted for comment about whether it plans to seek wider approval for use on the NHS. Julian Beach, MHRA interim executive director of healthcare quality and access, said: 'Patient safety is our top priority, which is why we're pleased to approve the first needle-free nasal spray formulation of adrenaline for the emergency treatment of anaphylaxis in the UK. 'Until now, adrenaline for self-administration has only been available via auto-injectors. 'While this represents an important new option, adrenaline auto-injectors remain a vital and potentially life-saving treatment, giving people experiencing anaphylaxis valuable time before emergency help arrives. 'We continue to encourage everyone at risk of severe allergic reactions, and those around them, to familiarise themselves with how to respond in an emergency. 'Resources and guidance are available on the MHRA website to help people be prepared.' Anaphylaxis is a sudden and life-threatening allergic reaction that can cause a drop in blood pressure and breathing difficulties. EURneffy is intended for use in adults and children who weigh 30kg (about 66lb) or more, and can be used even if people have colds or blocked noses. It is a single dose nasal spray that delivers its entire contents (2mg) upon activation. People are reminded that the plunger should not be pressed before inserting the product into the nostril, otherwise the single dose will be lost. The MHRA said patients should always carry two nasal sprays with them in case a second dose is needed, and tell family and friends where it is.
The Guardian
18-07-2025
- Health
- The Guardian
Hay fever making the summer of ‘25 sneezy? We're here to help
When the sun's shining and you're itching to join in at festivals, picnics and outdoor fun, a nasal spray could turn your summer from 'meh' to 'mega' Buy Beconase now on Amazon Beconase Hayfever Relief for Adults 0.05% Nasal Spray contains beclometasone dipropionate. For the treatment of hayfever and symptomatic relief from nasal congestion, runny nose, sneezing, itchy nose, eye symptoms (such as itching, watering, redness) and associated sinus discomfort in adults aged 18 and over. Always read the leaflet. MAT-9522
